These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27419209)

  • 1. Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes.
    Tajiri Y; Kawano S; Hirao S; Oshige T; Iwata S; Ono Y; Inada C; Akashi T; Hayashi H; Sato Y; Tojikubo M; Yamada K
    Int Sch Res Notices; 2014; 2014():639489. PubMed ID: 27419209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
    Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.
    Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M
    Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ; Liu XJ; Bai L; Yu Q; Zhang QM; Yu P; Yu DM
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
    Takai M; Ishikawa M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2019 May; 11(5):311-320. PubMed ID: 31019624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy.
    Takahara M; Shiraiwa T; Kaneto H; Katakami N; Matsuoka TA; Shimomura I
    Endocr J; 2012; 59(12):1131-6. PubMed ID: 22850206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.
    Harashima SI; Ogura M; Tanaka D; Fukushima T; Wang Y; Koizumi T; Aono M; Murata Y; Seike M; Inagaki N
    Int J Clin Pract; 2012 May; 66(5):465-76. PubMed ID: 22512606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes.
    Kodera R; Shikata K; Nakamura A; Okazaki S; Nagase R; Nakatou T; Haisa S; Hida K; Miyashita K; Makino H
    Intern Med; 2017; 56(6):605-613. PubMed ID: 28321057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
    Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
    Hong SM; Park CY; Hwang DM; Han KA; Lee CB; Chung CH; Yoon KH; Mok JO; Park KS; Park SW
    Diabetes Obes Metab; 2017 May; 19(5):654-663. PubMed ID: 28058750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
    Harashima SI; Tanaka D; Yamane S; Ogura M; Fujita Y; Murata Y; Seike M; Koizumi T; Aono M; Wang Y; Inagaki N
    Horm Metab Res; 2013 Mar; 45(3):231-8. PubMed ID: 22972180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin.
    Takahara M; Shiraiwa T; Katakami N; Matsuoka TA; Shimomura I
    Diabetes Technol Ther; 2014 Oct; 16(10):633-9. PubMed ID: 24949654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
    Hong ES; Khang AR; Yoon JW; Kang SM; Choi SH; Park KS; Jang HC; Shin H; Walford GA; Lim S
    Diabetes Obes Metab; 2012 Sep; 14(9):795-802. PubMed ID: 22443183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.